Pathways

Apixaban is an oral anticoagulant drug that competitively inhibits free and bound coagulation factor X in the clotting cascade. This mechanism of action prevents the formation of a thrombus otherwise known as a blood clot. Administered orally, this drug is typically used for the prevention of strokes or systemic embolism. Used in the treatment and prevention of recurrent thromboembolic diseases, such as deep vein thrombosis and pulmonary embolisms. Apixaban is metabolized by both CYP3A4 and P-glycoprotein (P-gp) and is known to increase in the blood when these are inhibited. Apixaban enters the bloodstream through the intestine by P-gp transport.

Apixaban (brand name Eliquis) is an oral anticoagulant drug that is a competitive inhibitor of free and bound factor Xa in the coagulation cascade. These effects will prevent the formation of a thrombus. This oral drug is typically used for the prevention of strokes or systemic embolism. It is also indicated in the treatment and reduction in risk of recurrent thromboembolic diseases, such as Deep Vein Thrombosis (DVT) and Pulmonary Embolisms (PE). Apixaban is a substrate for both CYP3A4 and P-glycoprotein (P-gp) and is known to increase in the blood when these are inhibited. Apixaban enters the bloodstream through the intestine by P-gp transport.

Antrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug used for the relief of mild to moderate pain. It targets the prostaglandin G/H synthase-1 (COX-1) and prostaglandin G/H synthase-2 (COX-2) in the cyclooxygenase pathway. The cyclooxygenase pathway begins in the cytosol with phospholipids being converted into arachidonic acid by the action of phospholipase A2. The rest of the pathway occurs on the endoplasmic reticulum membrane, where prostaglandin G/H synthase 1 & 2 converts arachidonic acid into prostaglandin H2. Prostaglandin H2 can either be converted into thromboxane A2 via thromboxane A synthase, prostacyclin/prostaglandin I2 via prostacyclin synthase or prostaglandin E2 via prostaglandin E synthase. COX-2 is an inducible enzyme, and during inflammation, it is responsible for prostaglandin synthesis. It leads to the formation of prostaglandin E2 which is responsible for contributing to the inflammatory response by activating immune cells and for increasing pain sensation by acting on pain fibers. Antrafenine inhibits the action of COX-1 and COX-2 on the endoplasmic reticulum membrane. This reduces the formation of prostaglandin H2 and therefore, prostaglandin E2 (PGE2). The low concentration of prostaglandin E2 attenuates the effect it has on stimulating immune cells and pain fibers, consequently reducing inflammation and pain. Fever is triggered by inflammatory and infectious diseases. Cytokines are produced in the central nervous system (CNS) during an inflammatory response. These cytokines induce COX-2 production that increases the synthesis of prostaglandin, specifically prostaglandin E2 which adjusts hypothalamic temperature control by increasing heat production. Because antrafenine decrease PGE2 in the CNS, it has an antipyretic effect.

Antrafenine (also named Stakane) acts as an anti-inflammatory and analgesic drug. It is not widely used as it has largely been replaced by newer drugs. Antrafenine can block prostaglandin synthesis by the action of inhibition of prostaglandin G/H synthase 1 and 2. Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway. Decreased prostaglandin synthesis in many animal model's cell is caused by presence of antrafenine.

Metabolites of Antipyrine are predicted with biotransformer.